NCT01897012 2019-01-28Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell LymphomasNational Cancer Institute (NCI)Phase 1 Completed26 enrolled
NCT02700022 2017-11-20A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell LymphomasUNC Lineberger Comprehensive Cancer CenterPhase 1 Terminated1 enrolled